5WK0 Stock Chart & Stats
€6.37
€0.00(0.00%)
At close: 4:00 PM EST
€6.37
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.17 - €11.10
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€28.66M
Enterprise Value€26.56
Total Cash (Recent Filing)€55.08M
Total Debt (Recent Filing)€4.35M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Jul 30, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.69
Shares Outstanding5,388,223
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€63.51Price Target Upside897.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.18
Revenue Forecast (FY)€26.13M
Bulls Say, Bears Say
Bulls Say
Strategic Licensing DealThe Amoytop license provides $25M upfront and sizable milestone/royalty upside while shifting development, regulatory and commercialization costs and risks in Greater China to a regional partner. This preserves cash, accelerates local market access, and secures data/IP sharing that can strengthen global HBV program durability.
Regulatory And Clinical ProgressFast Track designation plus interim Phase 2 results and a safety board recommendation to expand a cohort signal a potentially accelerated regulatory path and emerging efficacy/tolerability evidence. These durable developments increase the candidate's probability of advancement and make future partnering or approval timelines more attainable.
Modest Financial LeverageLow debt levels reduce refinancing and interest obligations, giving the company flexibility to fund R&D via equity or partnerships rather than servicing heavy borrowings. This structural balance-sheet strength lowers insolvency risk and supports strategic options across 2–6 months while clinical programs progress.
Bears Say
Persistent Cash BurnAs a clinical-stage biotech, Aligos runs sustained negative operating and free cash flow driven by trial and development costs. Absent material commercial revenue, this structural cash burn requires recurrent financing or partner monetization and creates execution risk if capital markets or partner payments delay.
Large Operating LossesPersistent, sizable operating losses erode equity and constrain the firm's ability to advance multiple programs simultaneously without dilution or costly partnerships. Even with high gross margins on limited revenue, the cost base far exceeds scale, making long-term sustainability contingent on trial success or recurring licensing.
No Commercial Revenue BaseLack of approved products means future revenues depend on successful development, approvals, or licensing. This structural absence of product cash flow forces reliance on equity raises or milestone payments, increasing dilution risk and exposing the business to timeline and regulatory uncertainties over the medium term.
Aligos Therapeutics News
5WK0 FAQ
What was Aligos Therapeutics, Inc.’s price range in the past 12 months?
Aligos Therapeutics, Inc. lowest stock price was €4.17 and its highest was €11.10 in the past 12 months.
What is Aligos Therapeutics, Inc.’s market cap?
Aligos Therapeutics, Inc.’s market cap is €28.66M.
When is Aligos Therapeutics, Inc.’s upcoming earnings report date?
Aligos Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were Aligos Therapeutics, Inc.’s earnings last quarter?
Aligos Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -€1.938 earnings per share for the quarter, beating the consensus estimate of -€1.941 by €0.003.
Is Aligos Therapeutics, Inc. overvalued?
According to Wall Street analysts Aligos Therapeutics, Inc.’s price is currently Undervalued.
Does Aligos Therapeutics, Inc. pay dividends?
Aligos Therapeutics, Inc. does not currently pay dividends.
What is Aligos Therapeutics, Inc.’s EPS estimate?
Aligos Therapeutics, Inc.’s EPS estimate is -0.96.
How many shares outstanding does Aligos Therapeutics, Inc. have?
Aligos Therapeutics, Inc. has 5,388,223 shares outstanding.
What happened to Aligos Therapeutics, Inc.’s price movement after its last earnings report?
Aligos Therapeutics, Inc. reported an EPS of -€1.938 in its last earnings report, beating expectations of -€1.941. Following the earnings report the stock price went up 3.578%.
Which hedge fund is a major shareholder of Aligos Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:5WK0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aligos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€63.51 (897.03% Upside)
€63.51 (897.03% Upside)
Blogger Sentiment
Bullish
DE:5WK0 Sentiment 70%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-57.16%
Trailing 12-Months
Company Description
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
5WK0 Stock 12 Month Forecast
Average Price Target
€63.51
▲(897.03% Upside)
Technical Analysis
Medicinova
―
Celularity
―
Barinthus Biotherapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―